Patients with HIV-1 RNA <40 copies/mL and target not detected outcome similar with dual DTG/3TC vs triple or quadruple TAF-based regimens.
At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.
Large, retrospective analysis illustrates viral suppression with and tolerability of dolutegravir-based regimens in children and adolescents who were treatment naive or suppressed on previous regimens.
In this real-world study, healthcare staff across a variety of clinic types found the implementation of monthly injectable cabotegravir + rilpivirine both feasible and acceptable despite disruptions due to COVID-19.
Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.
After 2-week oral lead-in, treatment with oral or subcutaneous lenacapavir plus FTC/TAF associated with high rates of virologic suppression.
Adherence to the dapivirine vaginal ring and oral PrEP was higher than anticipated over 12 months, with rates reaching 50% to 59% depending on the modality.
While the number of PrEP breakthrough infections was small, there was a high frequency of ART resistance in HIV-infected persons on TDF-based PrEP in Kenya, Zimbabwe, Eswatini, and South Africa.
In patients with multidrug-resistant HIV-1 infection, lenacapavir in combination with an optimized background regimen demonstrated a high rate of virologic suppression, a clinically meaningful increase in CD4+ cell count, and no discontinuation of study therapy due to adverse events through 26 weeks.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.